Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
暂无分享，去创建一个
[1] M. D. de Bruin‐Weller,et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. , 2018, The journal of allergy and clinical immunology. In practice.
[2] J. Perry,et al. Cicatricial ectropion in a patient treated with dupilumab , 2017, American journal of ophthalmology case reports.
[3] Mitchell A Jackson,et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment , 2017, Current opinion in ophthalmology.
[4] P. Majmudar,et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study , 2016, Cornea.
[5] J. Pepose,et al. Rethinking dry eye disease: a perspective on clinical implications. , 2014, The ocular surface.
[6] Kathryn S. Kennedy,et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. , 2014, Ophthalmology.
[7] Angus McFadyen,et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. , 2006, Investigative ophthalmology & visual science.